Efficacy of Dupilumab for Severe Atopic Dermatitis Co-occurring With Asthma in a Real-World Setting

J Investig Allergol Clin Immunol. 2023 Jun;33(3):217-219. doi: 10.18176/jiaci.0837. Epub 2022 Jun 20.

Authors

K Pose¹, D Laorden², N Hernández³, E Villamañán⁴, S Quirce^{1

5

6}, J Domínguez-Ortega^{1

5}

Affiliations

¹ Department of Allergy, La Paz University Hospital, Madrid, Spain.
² Department of Pulmonology, La Paz University Hospital, Madrid, Spain.
³ Department of Dermatology, La Paz University Hospital, Madrid, Spain.
⁴ Department of Hospital Pharmacy, La Paz University Hospital, Madrid, Spain.
⁵ La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.
⁶ CIBER of Respiratory Diseases (CIBERES), Madrid, Spain.

PMID: 37318773
DOI: 10.18176/jiaci.0837

No abstract available

Keywords: Asthma; Dupilumab; IL-13; Severe atopic dermatitis; Type 2 inflammatory diseases.

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Asthma* / complications
Asthma* / drug therapy
Dermatitis, Atopic* / drug therapy
Humans
Severity of Illness Index
Treatment Outcome

Substances

dupilumab
Antibodies, Monoclonal, Humanized